Cidofovir for cytomegalovirus (CMV) antigenemia after allogeneic stem cell transplantation.

被引：0
|
作者：
Soligo, D [1 ]
Tagliaferri, E [1 ]
Barraco, F [1 ]
Lambertenghi, D [1 ]
Della Volpe, A [1 ]
Deliliers, GL [1 ]
机构：
[1] Osped Maggiore, IRCCS, Ctr Trapianti Midollo, Milan, Italy
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4461
引用
收藏
页码：339B / 339B
页数：1
相关论文
共 50 条
  • [1] Pre-emptive therapy against cytomegalovirus (CMV) diseases guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation.
    Ohnishi, M
    Kanda, Y
    Saito, T
    Niiya, H
    Nakai, K
    Takeuchi, T
    Tanosaki, R
    Kunitoh, H
    Kobayashi, Y
    Tobinai, K
    Mineishi, S
    Takaue, Y
    BLOOD, 2000, 96 (11) : 342B - 342B
  • [2] Valganciclovir for the early prophylaxis of cytomegalovirus (CMV) infection after allogeneic stem cell transplantation.
    Bachier, C
    Shaughnessy, P
    Wall, D
    Grimley, M
    Carrum, G
    Freytes, C
    Callander, N
    Walsh, T
    LeMaistre, CF
    BLOOD, 2004, 104 (11) : 352B - 352B
  • [3] Response: Cidofovir against cytomegalovirus after allogeneic stem cell transplantation
    Ljungman, P
    Cordonnier, C
    BLOOD, 2001, 98 (05) : 1628 - 1628
  • [4] Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation
    Mori, T
    Mori, S
    Kanda, Y
    Yakushiji, K
    Mineishi, S
    Takaue, Y
    Gondo, H
    Harada, M
    Sakamaki, H
    Yajima, T
    Iwao, Y
    Hibi, T
    Okamoto, S
    BONE MARROW TRANSPLANTATION, 2004, 33 (04) : 431 - 434
  • [5] Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation
    T Mori
    S Mori
    Y Kanda
    K Yakushiji
    S Mineishi
    Y Takaue
    H Gondo
    M Harada
    H Sakamaki
    T Yajima
    Y Iwao
    T Hibi
    S Okamoto
    Bone Marrow Transplantation, 2004, 33 : 431 - 434
  • [6] Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation
    Platzbecker, U
    Bandt, D
    Thiede, C
    Helwig, A
    Freiberg-Richter, J
    Schuler, U
    Plettig, R
    Geissler, G
    Rethwilm, A
    Ehninger, G
    Bornhäuser, M
    TRANSPLANTATION, 2001, 71 (07) : 880 - 885
  • [7] Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study
    S Moretti
    P Zikos
    MT Van Lint
    E Tedone
    D Occhini
    F Gualandi
    T Lamparelli
    N Mordini
    G Berisso
    S Bregante
    B Bruno
    A Bacigalupo
    Bone Marrow Transplantation, 1998, 22 : 175 - 180
  • [8] Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT):: a randomised study
    Moretti, S
    Zikos, P
    Van Lint, MT
    Tedone, E
    Occhini, D
    Gualandi, F
    Lamparelli, T
    Mordini, N
    Berisso, G
    Bregante, S
    Bruno, B
    Bacigalupo, A
    BONE MARROW TRANSPLANTATION, 1998, 22 (02) : 175 - 180
  • [9] Cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT)
    Trenschel, R
    Ross, S
    Runde, V
    Retzlaff, S
    Ottinger, H
    Kohl, D
    Roggendorf, M
    Schaefer, UW
    BONE MARROW TRANSPLANTATION, 1999, 23 : S68 - S68
  • [10] Donor and recipient CMV status and the risk of CMV activation after allogeneic stem cell transplantation.
    Juvonen, E
    Ruutu, T
    Eriksson, B
    Remes, K
    Volin, L
    Remberger, M
    Parkkali, T
    Hägglund, H
    Ringdén, O
    BLOOD, 2001, 98 (11) : 396A - 396A
12345